• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.孕激素受体配体结合域激动状态的 X 射线结构揭示了 11β-取代甾体混合谱的不同作用机制。
J Biol Chem. 2012 Jun 8;287(24):20333-43. doi: 10.1074/jbc.M111.308403. Epub 2012 Apr 25.
2
The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation.RU486与处于不稳定激动构象的孕酮受体结合的X射线结构。
J Biol Chem. 2009 Jul 17;284(29):19572-9. doi: 10.1074/jbc.M109.007872. Epub 2009 Apr 16.
3
Discovery, chemistry, and reproductive pharmacology of asoprisnil and related 11beta-benzaldoxime substituted selective progesterone receptor modulators (SPRMs).阿索普瑞尼及相关11β-苯甲醛肟取代的选择性孕激素受体调节剂(SPRMs)的发现、化学及生殖药理学
Semin Reprod Med. 2005 Feb;23(1):58-73. doi: 10.1055/s-2005-864034.
4
A structural and in vitro characterization of asoprisnil: a selective progesterone receptor modulator.阿索普瑞尼尔的结构与体外特性:一种选择性孕激素受体调节剂
Mol Endocrinol. 2007 May;21(5):1066-81. doi: 10.1210/me.2006-0524. Epub 2007 Mar 13.
5
Progesterone receptor and the mechanism of action of progesterone antagonists.孕激素受体与孕激素拮抗剂的作用机制
J Steroid Biochem Mol Biol. 1995 Jun;53(1-6):449-58. doi: 10.1016/0960-0760(95)00091-d.
6
Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system.T47D细胞中孕激素受体调节剂的全基因组表达谱分析提供了一种新的分类系统。
J Steroid Biochem Mol Biol. 2009 Jan;113(1-2):105-15. doi: 10.1016/j.jsbmb.2008.11.015. Epub 2008 Dec 14.
7
Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators.一组化学相关的孕激素受体调节剂激动剂和拮抗剂的作用机制研究
J Biol Chem. 2011 Oct 7;286(40):35079-86. doi: 10.1074/jbc.M111.273029. Epub 2011 Aug 17.
8
Partial agonist activity of the progesterone receptor antagonist RU486 mediated by an amino-terminal domain coactivator and phosphorylation of serine400.由氨基末端结构域共激活因子和丝氨酸400磷酸化介导的孕酮受体拮抗剂RU486的部分激动剂活性。
Mol Endocrinol. 2010 Feb;24(2):335-45. doi: 10.1210/me.2008-0081. Epub 2009 Dec 11.
9
Agonist and antagonists induce homodimerization and mixed ligand heterodimerization of human progesterone receptors in vivo by a mammalian two-hybrid assay.通过哺乳动物双杂交试验,激动剂和拮抗剂在体内诱导人孕激素受体的同源二聚化和混合配体异源二聚化。
Mol Endocrinol. 1998 Dec;12(12):1914-30. doi: 10.1210/mend.12.12.0210.
10
A new generation of progesterone receptor modulators.新一代孕酮受体调节剂。
Steroids. 2008 Aug;73(7):689-701. doi: 10.1016/j.steroids.2008.03.005. Epub 2008 Mar 28.

引用本文的文献

1
Ancient and modern mechanisms compete in progesterone receptor activation.古今机制在孕激素受体激活方面相互竞争。
RSC Chem Biol. 2024 Apr 15;5(6):518-529. doi: 10.1039/d4cb00002a. eCollection 2024 Jun 5.
2
Identification of ELK1 interacting peptide segments in the androgen receptor.鉴定雄激素受体中 ELK1 的相互作用肽段。
Biochem J. 2022 Jul 29;479(14):1519-1531. doi: 10.1042/BCJ20220297.
3
Structural overview and perspectives of the nuclear receptors, a major family as the direct targets for small-molecule drugs.核受体的结构概述和展望,作为小分子药物的直接靶点,这一家族非常重要。
Acta Biochim Biophys Sin (Shanghai). 2022 Jan 25;54(1):12-24. doi: 10.3724/abbs.2021001.
4
Functional Effects In Silico Prediction for Androgen Receptor Ligand-Binding Domain Novel I836S Mutation.雄激素受体配体结合域新型I836S突变的计算机模拟功能效应预测
Life (Basel). 2021 Jul 6;11(7):659. doi: 10.3390/life11070659.
5
EC313-a tissue selective SPRM reduces the growth and proliferation of uterine fibroids in a human uterine fibroid tissue xenograft model.EC313-a 组织选择性 SPRM 可减少人子宫肌瘤组织异种移植模型中子宫肌瘤的生长和增殖。
Sci Rep. 2019 Nov 21;9(1):17279. doi: 10.1038/s41598-019-53467-w.
6
Ligand induced dissociation of the AR homodimer precedes AR monomer translocation to the nucleus.配体诱导的 AR 同源二聚体解离先于 AR 单体向核内易位。
Sci Rep. 2019 Nov 13;9(1):16734. doi: 10.1038/s41598-019-53139-9.
7
Ligand Binding Induces Agonistic-Like Conformational Adaptations in Helix 12 of Progesterone Receptor Ligand Binding Domain.配体结合诱导孕酮受体配体结合域螺旋12中类似激动剂的构象适应。
Front Chem. 2019 May 7;7:315. doi: 10.3389/fchem.2019.00315. eCollection 2019.
8
Progestin therapy to prevent preterm birth: History and effectiveness of current strategies and development of novel approaches.孕激素治疗预防早产:当前策略的历史和有效性以及新方法的发展。
Placenta. 2019 Apr;79:46-52. doi: 10.1016/j.placenta.2019.01.018. Epub 2019 Jan 28.
9
Exploring Flexibility of Progesterone Receptor Ligand Binding Domain Using Molecular Dynamics.利用分子动力学探索孕酮受体配体结合域的灵活性
PLoS One. 2016 Nov 8;11(11):e0165824. doi: 10.1371/journal.pone.0165824. eCollection 2016.
10
Progesterone-targeted magnetic resonance imaging probes.孕酮靶向磁共振成像探针。
Bioconjug Chem. 2014 Aug 20;25(8):1428-37. doi: 10.1021/bc500265h. Epub 2014 Jul 25.

本文引用的文献

1
Structural basis for agonism and antagonism for a set of chemically related progesterone receptor modulators.一组化学相关的孕激素受体调节剂激动剂和拮抗剂的作用机制研究
J Biol Chem. 2011 Oct 7;286(40):35079-86. doi: 10.1074/jbc.M111.273029. Epub 2011 Aug 17.
2
Unexpected binding orientation of bulky-B-ring anti-androgens and implications for future drug targets.意想不到的大 B 环抗雄激素的结合取向及其对未来药物靶点的影响。
J Med Chem. 2011 Jun 9;54(11):3973-6. doi: 10.1021/jm2000097. Epub 2011 May 16.
3
Discovery and optimisation of a selective non-steroidal glucocorticoid receptor antagonist.发现并优化一种选择性非甾体糖皮质激素受体拮抗剂。
Bioorg Med Chem Lett. 2011 Jan 1;21(1):137-40. doi: 10.1016/j.bmcl.2010.11.054. Epub 2010 Nov 16.
4
Improving the developability profile of pyrrolidine progesterone receptor partial agonists.改善吡咯烷孕激素受体部分激动剂的可开发性特征。
Bioorg Med Chem Lett. 2010 Jan 1;20(1):371-4. doi: 10.1016/j.bmcl.2009.10.092. Epub 2009 Oct 25.
5
Molecular switch in the glucocorticoid receptor: active and passive antagonist conformations.糖皮质激素受体中的分子开关:活性和被动拮抗剂构象。
J Mol Biol. 2010 Jan 22;395(3):568-77. doi: 10.1016/j.jmb.2009.11.011. Epub 2009 Nov 11.
6
Rational design of orally-active, pyrrolidine-based progesterone receptor partial agonists.基于吡咯烷的口服活性孕酮受体部分激动剂的合理设计。
Bioorg Med Chem Lett. 2009 Aug 15;19(16):4777-80. doi: 10.1016/j.bmcl.2009.06.055. Epub 2009 Jun 17.
7
The X-ray structure of RU486 bound to the progesterone receptor in a destabilized agonistic conformation.RU486与处于不稳定激动构象的孕酮受体结合的X射线结构。
J Biol Chem. 2009 Jul 17;284(29):19572-9. doi: 10.1074/jbc.M109.007872. Epub 2009 Apr 16.
8
Met909 plays a key role in the activation of the progesterone receptor and also in the high potency of 13-ethyl progestins.甲硫氨酸909在孕激素受体的激活以及13-乙基孕激素的高效能方面发挥着关键作用。
Mol Pharmacol. 2009 Jun;75(6):1317-24. doi: 10.1124/mol.108.054312. Epub 2009 Mar 16.
9
Global gene expression profiling of progesterone receptor modulators in T47D cells provides a new classification system.T47D细胞中孕激素受体调节剂的全基因组表达谱分析提供了一种新的分类系统。
J Steroid Biochem Mol Biol. 2009 Jan;113(1-2):105-15. doi: 10.1016/j.jsbmb.2008.11.015. Epub 2008 Dec 14.
10
Effect of B-ring substitution pattern on binding mode of propionamide selective androgen receptor modulators.B环取代模式对丙酰胺选择性雄激素受体调节剂结合模式的影响。
Bioorg Med Chem Lett. 2008 Oct 15;18(20):5567-70. doi: 10.1016/j.bmcl.2008.09.002. Epub 2008 Sep 5.

孕激素受体配体结合域激动状态的 X 射线结构揭示了 11β-取代甾体混合谱的不同作用机制。

X-ray structures of progesterone receptor ligand binding domain in its agonist state reveal differing mechanisms for mixed profiles of 11β-substituted steroids.

机构信息

Departments of Molecular Design and Informatics, MSD, P. O. Box 20, 5340 BH, Oss, The

出版信息

J Biol Chem. 2012 Jun 8;287(24):20333-43. doi: 10.1074/jbc.M111.308403. Epub 2012 Apr 25.

DOI:10.1074/jbc.M111.308403
PMID:22535964
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3370215/
Abstract

We present here the x-ray structures of the progesterone receptor (PR) in complex with two mixed profile PR modulators whose functional activity results from two differing molecular mechanisms. The structure of Asoprisnil bound to the agonist state of PR demonstrates the contribution of the ligand to increasing stability of the agonist conformation of helix-12 via a specific hydrogen-bond network including Glu(723). This interaction is absent when the full antagonist, RU486, binds to PR. Combined with a previously reported structure of Asoprisnil bound to the antagonist state of the receptor, this structure extends our understanding of the complex molecular interactions underlying the mixed agonist/antagonist profile of the compound. In addition, we present the structure of PR in its agonist conformation bound to the mixed profile compound Org3H whose reduced antagonistic activity and increased agonistic activity compared with reference antagonists is due to an induced fit around Trp(755), resulting in a decreased steric clash with Met(909) but inducing a new internal clash with Val(912) in helix-12. This structure also explains the previously published observation that 16α attachments to RU486 analogs induce mixed profiles by altering the binding of 11β substituents. Together these structures further our understanding of the steric and electrostatic factors that contribute to the function of steroid receptor modulators, providing valuable insight for future compound design.

摘要

我们在此呈现了孕激素受体(PR)与两种混合配体调节剂复合物的 X 射线结构,其功能活性源自两种不同的分子机制。与激动剂状态的 PR 结合的 Asoprisnil 结构表明,配体通过包括 Glu(723)在内的特定氢键网络有助于增加螺旋-12 激动剂构象的稳定性。当全拮抗剂 RU486 与 PR 结合时,这种相互作用不存在。与先前报道的 Asoprisnil 与受体拮抗剂状态结合的结构相结合,该结构扩展了我们对化合物混合激动剂/拮抗剂特性背后复杂分子相互作用的理解。此外,我们还呈现了 PR 在其激动剂构象中与混合配体化合物 Org3H 结合的结构,与参考拮抗剂相比,其拮抗活性降低而激动活性增加,这是由于 Trp(755)周围的诱导契合,导致与 Met(909)的空间冲突减少,但在螺旋-12 中诱导与 Val(912)的新内部冲突。该结构还解释了先前发表的观察结果,即 RU486 类似物的 16α 连接通过改变 11β 取代基的结合诱导混合特性。这些结构共同加深了我们对甾体受体调节剂功能的立体和静电因素的理解,为未来的化合物设计提供了有价值的见解。